Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intestinal epithelial cells are specialized cells that form the single-cell thick layer lining the intestinal tract, acting as both a physical barrier and an active participant in the host's mucosal immune response. They express a range of pattern recognition receptors (such as TLRs, NLRs, and RLRs) and produce antimicrobial peptides, cytokines, and chemokines to regulate the local immune environment. IECs sense luminal microbes and danger signals, communicate with immune cells in the lamina propria, and participate in immune tolerance and defense against infection. Disruption of IEC barrier or immune functions is associated with numerous intestinal diseases, including infections, chronic inflammation, and impaired healing. The immune response coordinated by IECs is essential for balancing host defense and tolerance of commensal microbiota.
Not applicable (for direct targeting). IECs may be affected indirectly by drugs targeting cytokines (e.g., TNF inhibitors, IL-10/protection, anti-IL-6/IL-17 agents), immunomodulatory drugs impacting barrier function, or antibiotics influencing microbiome-epithelial interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intestinal epithelial cell immune response (IEC).